Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
FP13 - Immunotherapy (Phase II/III Trials)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Type: Posters (Featured)
- Track: Immunotherapy (Phase II/III Trials)
-
+
FP13.04 - KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
00:00 - 00:00 | Presenter: Byoung Chul Cho
- Abstract
Loading...
-
+
P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P14.13 - Notch Family Gene Mutations Predict Clinical Benefit from Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Huaqiang Zhou
- Abstract
Loading... -
+
P14.14 - PTPRD: A Positive Predictive Biomarker for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jiayi Shen
- Abstract
Loading...
-
+
P76 - Targeted Therapy - Clinically Focused - EGFR
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Targeted Therapy - Clinically Focused
-
+
P76.34 - Exosomal miRNAs Participate in Osimertinib Resistance Mainly Through Bypass Activation Mechanisms in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Tangfeng Lv
- Abstract
Loading... -
+
P76.40 - Molecular Characteristics and Response to EGFR TKIs of EGFR L747 Position Mutation in Lung Cancer Patients.
00:00 - 00:00 | Presenter: Wenfeng Fang
- Abstract
Loading... -
+
P76.90 - Molecular Characteristics of BRAF Mutations in EGFR Mutant NSCLC after Progression on EGFR TKIs and Response to Combination Targeted Therapy
00:00 - 00:00 | Presenter: Wenfeng Fang
- Abstract
Loading...
-
+
OA02 - Updates in Locally Advanced NSCLC
- 09:15 - 10:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Locoregional and Oligometastatic Disease
-
+
OA02.06 - PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC
09:45 - 09:55 | Presenter: Nan Bi
- Abstract
Loading...
-
+
ES26 - Future Horizons in the Management of Small Cell Lung Cancer
- 14:15 - 15:15
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Small Cell Lung Cancer/NET
-
+
ES26.01 - DDR/PARP as a Target
14:15 - 14:30 | Presenter: Li Zhang
- Abstract
No abstract available for this presentation
